Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 17, 2008. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the SmithKline Beecham Mid-Term Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to dividend reinvestment.
Material Changes
There are no material changes to financial performance reported. The filing details an increase in Ordinary Share ADR holdings for specific individuals following the reinvestment of dividends paid on January 10, 2008.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) regarding the following transactions at a price of $54.11 per ADR:
- Dr JP Garnier: 1,773.02 ADRs
- Mr D J Phelan: 341.96 ADRs
- Mr D M Stout: 136.68 ADRs
Investor Verification Points
- Verify the dividend reinvestment price of $54.11 per ADR against market data for January 17, 2008.
- Confirm the total number of ADRs held by the named directors post-transaction.
- Review the full SmithKline Beecham Mid-Term Incentive Plan terms to understand the reinvestment mechanism.